Analyst consensus rating
Beam Therapeutics Analyst Rating: none
BEAM is rated none by 13 analysts with a $52.15 target. As of 2026-08-24.
Direct answer
Beam Therapeutics's consensus rating is none.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $52.15.
Forecast evidence checked August 24, 2026.
Get free Beam Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $28.52
- Average price target
- $52.15
- High price target
- $80.00
- Low price target
- $26.00
- Low target gap
- -8.8%
- Target upside
- +82.9%
- High target gap
- +180.5%
- Target range width
- 189.3%
- Consensus rating
- none
- Analysts
- 13
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Beam Therapeutics?
Beam Therapeutics has a verified none consensus. The same dataset has an average price target of $52.15.
How far are Beam Therapeutics's low and high targets from the recorded price?
The low target implies -8.8%, while the high target implies +180.5%.
How many analysts are included in Beam Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Beam Therapeutics's target upside or downside calculated?
The average target of $52.15 is divided by the recorded price of $28.52, then one is subtracted to produce +82.9%. This does not guarantee a future return.
When was Beam Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.